The Biden-Harris Administration has proposed a new rule to expand coverage of anti-obesity medications for Americans with Medicare and Medicaid, sending the shares of Wegovy maker Novo Nordisk (NVO) and
The Biden-Harris Administration has proposed a new rule to expand coverage of anti-obesity medications for Americans with Medicare and Medicaid, sending the shares of Wegovy maker Novo Nordisk (NVO) and
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President-elect Trump with this daily recap
Notable gainers among liquid option names this morning include J.M. Smucker (SJM) $122.32 +8.70, NRG Energy (NRG) $97.94 +6.07, Constellation Energy (CEG) $260.30 +11.37, Vistra Energy (VST) $160.74 +6.60, and
Deutsche Bank says Amgen’s (AMGN) MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being
Leerink notes that Amgen’s (AMGN) Phase 2 MariTide showed “up to ~20% average weight loss at 52 weeks” in nondiabetic obese/overweight patients, which is roughly on par with the highest,